RT期刊文章SR电子T1独立脑脊液和血液中HIV病毒复制病毒隔离在抗逆转录病毒治疗期间摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 355 OP 361 10.1212 / WNL.56.3.355 VO 56是3 A1 K。首页Stingele A1 j·哈斯A1 t·齐默尔曼A1 r . Stingele A1 c Hubsch-Muller A1 m . Freitag A1 b Storch-Hagenlocher A1 m·哈特曼A1 b Wildemann年2001 UL //www.ez-admanager.com/content/5首页6/3/355.abstract AB背景:艾滋病病毒感染者高活性抗逆转录病毒疗法的目标是减少血浆病毒载量(六世)低于可量化的水平。在hiv - 1突变与耐药相关基因可以限制治疗成功。低能见度水平涉及一个低风险的抗药性突变体的出现。是否有不同的发展,艾滋病病毒毒株在不同生物间并不理解。方法:作者研究了六世和突变产生抗性的发生在病毒基因组与血液和脑脊液样本23感染艾滋病毒的病人。他们决定的hiv - 1 RNA逆转录酶聚合酶链反应扩增和序列直接测序。他们测量阻力抗逆转录病毒药物遗传型的与毒品有关的点突变的检测和六世branched-DNA化验。结果:放大的艾滋病毒是成功的,即使在患者血浆和CSF六世低于检出限。六世CSF与血液中相当低(p < 0.0001)。 There was no correlation between CSF and plasma VL. The mutational pattern in viral copies derived from blood and CSF was not identical. Ten (9%) of the total number of 118 mutations associated with drug resistance occurred in blood isolates only; 14 (11%) were detected exclusively in CSF strains. Conclusion: There is evidence for viral replication at HIV RNA levels less than 50/mL. The results suggest divergent evolution of HIV-1 in different biologic compartments. The presence of resistant mutants in the CSF may escape regular diagnostic in blood. Therapeutic success may fail after adapting therapy to genotypic resistance patterns detected in one compartment only.

map